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ABSTRACT
Preceding infections and anti-ganglioside anti-
bodies were assessed among 80 Guillain–Barre´
syndrome (GBS) patients and 125 controls. Previ-
ous infections were more frequent among GBS
patients than among controls (p <0.0001), and had
a signiﬁcant association with axonal subtype
compared with acute inﬂammatory demyelinat-
ing polyneuropathy (AIDP) (29 ⁄ 46 vs. 10 ⁄ 34
patients; p <0.05). Campylobacter jejuni (26%) was
the most common preceding infection among GBS
patients, followed by Mycoplasma pneumoniae
(15%). Anti-ganglioside antibodies were detected
more frequently among GBS patients than
among controls (65 ⁄ 80 vs. 13 ⁄ 125; p <0.001), and
a higher proportion of axonal cases had these
antibodies than did AIDP patients (43 ⁄ 46 vs.
22 ⁄ 34; p <0.01).
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Guillain–Barre´ syndrome (GBS) is a common
cause of acute ﬂaccid paralysis, with an annual
incidence of 1–2 cases ⁄ 100 000 population [1]. The
pathological spectrum of GBS includes acute
inﬂammatory demyelinating polyneuropathy
(AIDP), acute motor axonal neuropathy (AMAN)
and acute motor sensory axonal neuropathy
(AMSAN). One-half to two-thirds of GBS patients
usually report antecedent infections, and Campy-
lobacter jejuni, cytomegalovirus (CMV), Epstein-
Barr virus (EBV) and Mycoplasma pneumoniae are
recognised triggering agents of GBS [2]. Anti-
ganglioside antibodies are believed to play an
important role in the pathogenesis of GBS because
of molecular mimicry between some glycocon-
jugate epitopes of microbes and the nerve tissue
of the host [3]. The present study investigated
commonly described microbial infections and
anti-ganglioside antibodies in patients grouped
according to GBS subtype.
Eighty GBS patients admitted to the neurology
ward, 80 healthy volunteers matched for age and
gender, and without any history of apparent
infectious illness at the time of sample collection,
and 45 patients with neurological diseases other
than GBS, were included in a prospective case-
control study between February 2001 and March
2005. GBS patients were deﬁned according to
criteria described previously [4] and were further
subdivided into GBS subtypes [5]. Single stool
and serum samples were collected from all GBS
patients and controls with other neurological
diseases within 24–48 h of admission.
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Previous C. jejuni, M. pneumoniae, CMV, EBV
and herpes simplex virus (HSV) infections were
assessed in all GBS patients and controls. C. jejuni
infection was detected by stool culture and PCR
[6] and by serum antibodies [2]. Serum dilutions
used were 1:500 and 1:1000 for IgM and IgG,
respectively. C. jejuni infection was deﬁned by at
least one of the following criteria: (i) stool culture
and ⁄ or PCR positive [6]; (ii) presence of IgG and
IgM antibodies; and (iii) high titre IgG antibody
with a history of diarrhoea within the 4-week
period preceding the onset of GBS [7]. Other
microbial infections were detected using commer-
cially available IgM ELISA kits. CMV infection
was conﬁrmed by measuring IgG avidity. Anti-
ganglioside antibodies against GM1, GD1a, GD1b,
GT1b, GM2 and GalC in the sera of patients and
controls were detected by ELISA according to
standard protocols [8,9].
Comparisons between the groups were made
using Z-tests for proportions and independent
two-tailed t-tests, with p <0.05 considered to be
signiﬁcant. Multiple logistic regression was used
to assess independent factors associated with
GBS. SPSS v.13.0 software (SPSS Inc., Chicago,
IL, USA) was used for data management and
analysis.
Demographical details of GBS patients and
controls are summarised in Table 1. The axonal
form (AMAN and AMSAN) of GBS was more
common among younger patients than AIDP
(mean age, axonal vs. AIDP, 25.5 ± 17.4 vs.
37.2 ± 21.6 years; p <0.001). Thirty-eight (48%)
GBS patients had a clinical history of at least
one recent infection (Table 1). AIDP and axonal
subtypes were more common among patients
with previous respiratory infection (p <0.05) and
diarrhoea (p <0.05). Evidence of preceding infec-
tion was documented in 39 (49%) GBS patients
and ten (8%) controls (Table 1), with C. jejuni
(26%) and M. pneumoniae (15%) infections being
associated strongly with GBS (Table 1). C. jejuni
infection was more frequent in association with
the axonal subtype than with the demyelinating
subtype (p <0.01). CMV, EBV and HSV infections
were present in 6%, 4% and 1% of GBS patients,
respectively.
One or more classes of anti-ganglioside anti-
bodies were present among 65 (81%) GBS
patients and 13 (10%) controls (p <0.001). More
GBS patients with the axonal subtype had anti-
ganglioside antibodies than did AIDP patients
(43 ⁄ 46, 93%, vs. 22 ⁄ 34, 66%; p <0.01). Anti-GM1
and anti-GD1a IgG antibodies were associated
with the axonal subtype (Table 2). In multiple
logistic regression, antecedent C. jejuni infection
(OR 5.9), anti-GM1 IgM (OR 9.6), anti-GM1 IgG
(OR 11.9), anti-GD1a IgG (OR 9.6) and anti-
AsGM1 IgG (OR 5.1) were associated independ-
ently with GBS.
Table 1. Demographical data and spectrum of infections for patients with Guillain–Barre´ syndrome (GBS) and controls
Demographical parameters
Subjects
GBS (n = 80)
HC DCAIDP
Axonal (n = 46)
AMAN AMSAN Total
Number of subjects 34 (43%) 27 (33%) 19 (24%) 46 (57%) 80 45
Mean age (years) 37.2 ± 21.6 26.3 ± 17.5 25.0 ± 17.4 25.5 ± 17.4 32.4 ± 7.26 34.3 ± 16.9
Gender (M:F) 26:8 20:7 11:8 31:15 58:22 34:11
Preceding illness
Respiratory infection (n = 17)a 12 (35%) 1 (4%) 4 (21%) 5 (11%) 0 2 (4%)
Diarrhoea with or without abdominal pain (n = 10)b 1 (3%) 6 (22%) 3 (16%) 9 (20%) 0 0
Fever (n = 11) 4 (12%) 5 (19%) 2 (11%) 7 (15%) 0 0
Chicken pox (n = 1) 1 (1%) 0 0 0 0 0
Infections
Campylobacter jejunic 2 (6%) 13 (48%) 6 (32%) 19 (41%) 4 (5%) 2 (4%)
Mycoplasma pneumoniaed 7 (21%) 3 (11%) 2 (11%) 5 (11%) 1 (1%) 1 (2%)
CMV 1 (3%) 3 (11%) 1 (5%) 4 (9%) 1 (1%) 1 (2%)
EBV 0 2 (7%) 1 (5%) 3 (7%) 0 0
HSV 0 0 1 (5%) 1 (2%) 0 0
HC, healthy controls; DC, controls with other neurological diseases.
AIDP, acute inﬂammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor sensory axonal neuropathy; CMV,
cytomegalovirus; EBV, Epstein-Barr virus; HSV, herpes simplex virus.
aRespiratory infection, AIDP vs. axonal, p <0.05.
bDiarrhoea, axonal vs. AIDP, p <0.05;
cC. jejuni infection, GBS vs. DC, p <0.001; GBS vs. HC, p < 0.001; axonal vs.AIDP, p <0.01.
dM. pneumoniae infection, GBS vs. DC, p <0.05; GBS vs. HC, p <0.01.
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Both axonal and AIDP subtypes were present
equally in the population investigated, which is in
contrast to studies from western and east ⁄Asian
countries [10]. GBS was more common among
males than among females, but was not associ-
ated with age; however, the axonal subtype
affected younger populations signiﬁcantly more
frequently (p <0.001), which is a ﬁnding not
reported previously.
Antecedent respiratory illness and diarrhoea
were associated signiﬁcantly with AIDP and
axonal subtype, respectively. Although recent
infections have been reported in 50–70% of GBS
patients [11], associations between clinical symp-
toms and GBS subtypes are not well-documented.
It is also believed that sub-clinical infections could
also trigger GBS [6]. Microbiological evidence of
infection was detected in signiﬁcantly higher num-
bers of GBS patients (49%) than in both groups of
controls (8%). C. jejuni and M. pneumoniae infec-
tions were associated with GBS, with GBS
patients having a high M. pneumoniae infection
rate (15%) compared with other published series
(5–6%) [12]. C. jejuni infection was present in 26%
of GBS patients, similar to the ﬁgures of 13–39%
reported from Europe and north America, but
much lower than those reported from China and
Japan [2]. As in other east ⁄Asian countries [13,14],
C. jejuni infection was linked strongly to axonal
subtype. Although CMV (6%) and EBV (2%)
infection rates in the present study were within
the ranges reported previously [2,12,15], the
proportions of both differed from those of the
controls. In contrast to a previous study [12], four
of ﬁve CMV-positive GBS patients had axonal
degeneration with no cranial nerve involvement.
HSV infection did not appear to be common in the
GBS patients studied.
Anti-ganglioside antibodies were found signi-
ﬁcantly more often in GBS patients than in
controls, and more patients with the axonal
subtype had anti-ganglioside antibodies than
did patients with the demyelinating subtype
(Table 2). Anti-GM1 IgG and IgM, and anti-
GD1a IgG antibodies, were detected more fre-
quently in GBS patients. Anti-GM1 IgG antibodies
have been found in >50% of GBS patients,
irrespective of the infectious serology [14], with
a prevalence of 0–81% [16]. Anti-GM1 IgG and
anti-GD1a IgG antibodies were associated signi-
ﬁcantly with the axonal subtype. It has been
reported that anti-GM1 IgG and anti-GD1a IgG
are relatively speciﬁc markers for axonal GBS [17],
but several studies have failed to correlate anti-
GM1 antibodies with electrodiagnostic ﬁndings
[8,13,18]. It has been speculated that anti-GD1a
IgG may have a more important role in the
pathogenesis of axonal GBS [19].
Table 2. Frequency of IgM and IgG anti-ganglioside antibodies in patients with Guillain–Barre´ syndrome (GBS) and
controls
Anti-ganglioside antibody
GBS Controls
Axonala (n = 46) AIDP (n = 34) Total (n = 80) DC (n = 45) HC (n = 80) Total (n = 125)
Any class 43b (93%) 22 b (65%) 65 (81%)c 10 (22%) 3 (4%) 13 (10%)c
Both classes 24 (52%) 9 (26%) 33 (41%) 3 (7%) 0 3 (2%)
Only IgM 2 (4%) 2 (6%) 4 (5%) 1 (2%) 0 1 (1%)
Only IgG 17 (40%) 11 (32%) 28 (35%) 6 (13%) 3 (4%) 9 (7%)
IgG
Anti- GM1d 30 (65%) 11 (32%) 41 (51%) 3 (7%) 3 (4%) 6 (5%)
Anti-GD1ae 24 (52%) 4 (12%) 28 (35%) 2 (4%) 0 2 (2%)
Anti-GD1b 7 (15%) 5 (15%) 12 (15%) 0 0 0
Anti-GT1b 8 (7%) 2 (21%) 10 (13%) 0 0 0
Anti-GM2 4 (9%) 3 (9%) 7 (9%) 4 (9%) 0 4 (3%)
Anti-GalC 5 (11%) 6 (18%) 11 (14%) 0 0 0
Anti-AsGM1 11 (24%) 5 (15%) 16 (20%) 0 0 0
IgM
Anti-GM1 21 (46%) 10 (29%) 31 (39%) 2 (4%) 0 2 (2%)
Anti-GD1a 14 (31%) 1 (3%) 15 (19%) 1 (2%) 0 1 (1%)
Anti-GD1b 1 (2%) 0 1 (1%) 0 0 0
Anti-GT1b 2 (4%) 0 2 (3%) 0 0 0
Anti-GM2 4 (9%) 3 (9%) 7 (9%) 1 (2%) 0 1 (1%)
Anti-GalC 1 (2%) 2 (6%) 3 (4%) 0 0 0
Anti-AsGM1 1 (2%) 1 (3%) 2 (3%) 0 0 0
HC, healthy controls; DC, controls with other neurological diseases; AIDP, acute inﬂammatory demyelinating polyneuropathy.
aAxonal includes acute motor axonal neuropathy (AMAN) and acute motor sensory axonal neuropathy (AMSAN).
bAxonal vs. AIDP, p <0.01.
cGBS vs. DC, p <0.001; GBS vs. HC, p <0.001.
dGM1 anti-ganglioside IgG antibodies, axonal vs. AIDP p <0.01.
eGD1a anti-ganglioside IgG antibodies, axonal vs. AIDP p <0.01.
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In conclusion, the axonal subtype of GBS affects
the younger population more commonly. In
addition to C. jejuni, M. pneumoniae infection
appears to be associated strongly with GBS cases.
Anti-ganglioside antibodies are detected more
frequently in cases of GBS, especially with the
axonal subtype.
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